Treatment Strategies for Transplant-ineligible NDMM Patients
|
|
- Rosaline Davidson
- 5 years ago
- Views:
Transcription
1 1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France
2 Multiple Myeloma affects primarily elderly patients 2 SEER: New MM Cases by Age Group Available from Accessed on 6/214.
3 Mean years of expected and observed survival and years of life lost Pooled analysis, 6996 patients : conventional CT, 3553 patients : transplant What means CURE for elderly and very elderly patients??? Ludwig H. et al, Journal of Clinical Oncology, 28, , 21
4 Period estimates of 1-year survival of patients with MM by major age groups in defined calendar periods from to Brenner et al; Blood 28; 111:
5 Patients (%) Dexamethasone-based Regimens vs.mp for Elderly NDMM Patients (IFM 95-1) Time (months) Treatment O/N Survival time median±se (month) MP 16/ ± 3.6 M + DEX 97/ ± 3.1 DEX 11/ ± 2. DEX + IFN 12/ ± 5.3 Facon T, et al. Blood. 26;17:
6 Refresher on MPT and VMP data A journey back in time... MPT: melphalan, prednisone, thalidomide VMP: bortezomib, melphalan, prednisone
7 MPT becomes a standard of care Facon T, et al. Lancet. 27;37: Fayers PM, et al. Blood. 211;118:
8 VMP becomes a standard of care San Miguel JF, et al. N Engl J Med. 28;359:
9 Both VMP and MPT are recognised standards of care in TNE NDMM patients 214: IMWG guidelines 1 Recommended treatments for patients not eligible for high-dose therapy, or in case the transplant procedure is not available, include MPT, MPV and CTD" 214: EMN guidelines 2 Bortezomib-melphalan-prednisone or melphalan-prednisone-thalidomide are the standards of care for transplant-ineligible patients" 214: NCCN guidelines 3 MPT and VMP are 2 of the five preferred primary regimens for nontransplant candidates with multiple myeloma 1. Ludwig H et al., Leukemia 213, in press. 2. Engelhardt M, et al. Haematologica. 214;99: NCCN Guidelines Multiple Myeloma. Version
10 MPT and VMP over time MPT: a stable standard of care thalidomide 1 (or 2 mg/day) MPV: an evolving standard of care from twice weekly to weekly 1,2 (21) from i.v. to s.c. 3 (212) subcutaneous weekly likely the current standard of care for VMP and other bortezomib-based regimens in the elderly 4 In case of renal impairment or extensive bone disease, twice weekly administration may be recommended 4 1. Palumbo A, et al. J Clin Oncol. 21;28: Mateos MV, et al. Lancet Oncol. 21;11: Moreau P, et al. Lancet Oncol. 211;12: Ludwig H, et al. Oncologist 214 in press.
11 Patients (%) Patients (%) MMIX & XI Trials: Cyclo-DEX + THAL (CTDa) vs. MP Cyclo: 5 mg weekly; Thal: 2 mg daily; Dex: 2 mg days 1-4; 9-12 RR (CR) (%): 64(13) vs. 33(2) 1 PFS 1 OS 8 CTDa MP P =.1 8 CTDa MP P = CTDa: 13m MP: 12.4m CTDa: 33m MP: 3m CTDa MP PFS (months) CTDa MP PFS (months) CTDa was one of the standard of care in UK It may be improved switching Thal for Len CRDa Morgan G. Blood 211; 118(5): ;Pawlyn CH. ASH213: abstract 54.
12 UPFRONT Study: VD vs. VTD vs. VMP 12 PFS (intent-to-treat population) OS (intent-to-treat population) PFS, progression-free survival; OS, overall survival; VD, bortezomib-dexamethasone; VTD, bortezomib-thalidomide-dexamethasone; VMP, bortezomibmelphalan-prednisone Niesvizky R et al, Blood 213; 122;abstract 1966.
13 13 Back to present day The benefits of continuous therapy in elderly patients
14 FIRST Trial: Study Design (Ph3 Pivotal Trial) RANDOMIZATION (N = 1,623) PD or unacceptable toxicity PD, OS and subsequent anti-mm Tx 14 Primary endpoint: PFS (Rd vs. MPT) Key secondary endpoints: OS, QoL, TTF, Time to 2 nd AMT, DOR, Safety Screening Arm A Continuous Rd (n = 535) Active Tx + PFS follow-up phase LEN + Lo-DEX continuously LENALIDOMIDE 25 mg D1-21/28 LoDEX 4 mg D1,8,15 & 22/28 Long-term follow-up Arm B Rd18 (n = 541) LEN + Lo-DEX 18 cycles (72 wks) LENALIDOMIDE 25 mg D1 21/28 LoDEX 4 mg D1,8,15 & 22/28 Arm C MPT (n = 547) MEL + PRED + THAL 12 cycles 1 (72 wks) MELPHALAN PREDNISONE THALIDOMIDE.25 mg/kg D1 4/42 2 mg/kg D1 4/42 2 mg D1 42/42 Pts > 75 yrs: LoDEX 2 mg D1, 8, 15 & 22/28; THAL 2 1 mg D1 42/42; MEL 2.2 mg/kg D1 4. AMT, anti-myeloma treatment; D, days; DOR, duration of response; LoDEX, low-dose dexamethasone; MM, multiple myeloma; OS, overall survival; PD, progressive disease; PFS, progression-free survival; pts, patients; QoL, quality of life; TTF, time to treatment failure, TX, treatment; wks, weeks. 1 Facon T, et al. Lancet. 27;37: Hulin C, et al. J Clin Oncol. 29;27: Facon T, et al. EHA 214: Abstract S643.
15 72 wks Patients (%) Patients (%) FIRST Trial: Final PFS and Interim OS 15 Final PFS Interim OS 1 Rd (n = 535) Rd18 (n = 541) Median PFS 25.5 mos 2.7 mos 1 4-year OS Rd (n = 535) 59.4% Rd18 (n = 541) 55.7% 8 6 MPT (n = 547) 21.2 mos Hazard ratio Rd vs. MPT:.72; P =.6 Rd vs. Rd18:.7; P =.1 Rd18 vs. MPT: 1.3; P = MPT (n = 547) 51.4% Hazard ratio Rd vs. MPT:.78; P =.168 Rd vs. Rd18:.9; P =.37 Rd18 vs. MPT:.88; P = PFS (mos) OS (mos) Facon T, et al. EHA 214: Abstract S643.
16 Age Analysis 16
17 FIRST Trial - Age Analysis: Adjusted Starting Doses 17 Adjustment 75 yrs > 75 yrs Drugs/Regimens LEN (21/28 days) CrCl: < 3 ml/min 15 mg QOD 15 mg QOD CrCl: 3-5 ml/min 1 mg 1 mg CrCl: > 5 ml/min 25 mg 25 mg DEX (1, 8, 15, 22/28 days) MEL (1-4/42 days) PRED (1-4/42 days) THAL (28/28 days) N/A 4 mg 2 mg CrCl: < 5 ml/min ANC < 1,5/µL Platelet count: < 1,/µL.25 mg/kg.2 mg/kg.125 mg/kg.1 mg/kg N/A 2 mg/kg 2 mg/kg N/A 2 mg 1 mg ANC, absolute neutrophil count; CrCl, creatinine clearance; DEX, dexamethasone; LEN, lenalidomide; MEL, melphalan; N/A, not applicable; PRED, prednisone; QOD, once every 2 days; THAL, thalidomide. Hulin C, et al. FIRST Trial Effect of Age in NDMM patients. ASH 214, abstract #81.
18 FIRST Trial - Age Analysis: Baseline Characteristics 18 Pt characteristics were well balanced across all Tx arms Characteristic Median age, yrs (range) Continuous Rd (N= 349) 7 (44 75) Age 75 yrs Rd18 (N= 348) 7 (4 75) MPT (N= 359) 7 (51 75) Continuous Rd (N= 186) 79 (76 91) Age > 75 yrs Rd18 (N= 193) 79 (76 89) MPT (N= 188) 79 (76 92) Male (%) ECOG PS 2 (%) ISS stage III (%) CrCl (%) < 3 ml/min and < 5 ml/min 5 and < 8 ml/min CrCl, creatinine clearance; ECOG, Eastern Cooperative Oncology Group; ISS, international staging system; MPT, melphalan-prednisone-thalidomide; PS, performance status; pt, patient; Rd, lenalidomide and low-dose dexamethasone; Rd18, Rd for 18 cycles; tx, treatment; yrs, years. Hulin C, et al. FIRST Trial Effect of Age in NDMM patients. ASH 214, abstract #81.
19 Pts (%) Pts (%) FIRST Trial - Age Analysis: PFS 19 Age 75 yrs Median (mos) Age > 75 yrs Median (mos) 1 Rd 27.4 Rd Rd 21.2 Rd MPT 21.8 MPT Hazard ratio (95% CI) Rd vs. MPT:.68 (.56.83) Rd vs. Rd18:.68 (.55.83) Rd18 vs. MPT: 1.1 ( ) 6 Hazard ratio (95% CI) Rd vs. MPT:.81 ( ) Rd vs. Rd18:.75 (.58.98) Rd18 vs. MPT: 1.8 ( ) 4 46% (Rd) 4 35% (Rd) 2 25% (Rd18) 23% (MPT) 2 19% (Rd18) 22% (MPT) PFS (mos) PFS (mos) Rd Rd Rd Rd MPT MPT mos, months; MPT, melphalan-prednisone-thalidomide; PFS, progression-free survival; pts, patients; Rd, lenalidomide and low-dose dexamethasone; Rd18, Rd for 18 cycles; yrs, years. Hulin C, et al. FIRST Trial Effect of Age in NDMM patients. ASH 214, abstract #81.
20 Pts (%) Pts (%) FIRST Trial - Age Analysis: OS Interim Analysis 2 Age 75 yrs Age > 75 yrs 1 3-yr OS Rd 74% 1 3-yr OS Rd 63% Rd18 7% Rd18 58% 8 MPT 67% 8 MPT 54% Rd Rd18 MPT OS (mos) Hazard ratio (95% CI) Rd vs. MPT:.77 ( ) Rd vs. Rd18:.88 ( ) Rd18 vs. MPT:.88 ( ) Rd Rd18 MPT OS (mos) Hazard ratio (95% CI) Rd vs. MPT:.8 ( ) Rd vs. Rd18:.94 ( ) Rd18 vs. MPT:.85 ( ) mos, months; MPT, melphalan-prednisone-thalidomide; OS, overall survival; pts, patients; Rd, lenalidomide and low-dose dexamethasone; Rd18, Rd for 18 cycles; yrs, years. Hulin C, et al. FIRST Trial Effect of Age in NDMM patients. ASH 214, abstract #81.
21 FIRST Trial - Renal Analysis: Characteristics 21 Patients: Of the 1,623 pts enrolled in the FIRST trial: 389 (24%) had normal renal function 715 (44%) had mild RI 372 (23%) had moderate RI 147 (9%) had severe RI Outcomes by Renal Subgroup: A significant benefit was seen with continuous Rd vs. Rd18 or MPT in pts with mild or moderate RI Continuous Rd vs. MPT, mild RI: HR =.74; P =.2 Continuous Rd vs. MPT, moderate RI: HR =.66; P <.1 At 36 mos a higher percentage of pts are still progression free in continuous Rd vs. Rd18 and MPT PFS, progression free survival; Rd, lenalidomide plus low-dose dexamethasone; Rd18, Rd for 18 cycles; MPT, melphalan-prednisone-thalidomide; pts, patients; RI, renal impairment; HR, hazard ratio; mos, months Dimopoulos MA, et al. FIRST trial: Impact of Renal Impairment in NDMM pts. ASH 214, abstract #2112.
22 FIRST Trial - Renal Analysis: PFS Per Status Survival probability Survival probability Survival probability Survival probability 22 PFS in normal (per IRAC assessment) PFS in mild RI (per IRAC assessment) 1..8 Continuous Rd Rd18 MPT 1..8 Continuous Rd Rd18 MPT Cont. Rd vs. MPT HR:.71, P =.5 a Rd vs. Rd18 HR:.67, P =.2 a Rd18 vs. MPT HR: 1.6, P =.76 a PFS (mos) PFS in moderate RI (per IRAC assessment) Continuous Rd Rd18 MPT.2 Cont. Rd vs. MPT HR:.74, P =.2 a Rd vs. Rd18 HR:.72, P <.1 a Rd18 vs. MPT HR: 1.4, P =.76 a PFS (mos) PFS in severe RI (per IRAC assessment) Continuous Rd Rd18 MPT Cont. Rd vs. MPT HR:.66, P <.1 a Rd vs. Rd18 HR:.66, P <.1 a Rd18 vs. MPT HR: 1.2, P =.89 a PFS (mos) a Nominal P values are presented for multiplicity assessments which need to be taken into consideration before making clinical interpretations. HR, hazard ratio; mos, months; MPT, melphalan-prednisone-thalidomide; PFS, progression-free survival; Rd, lenalidomide plus low-dose dexamethasone; Rd18, Rd for 18 cycles; RI, renal impairment; IRAC, Independent Response Adjudication Committee Dimopoulos MA, et al. FIRST trial: Impact of Renal Impairment in NDMM pts. ASH 214, abstract # Cont. Rd vs. MPT HR:.76, P =.31 a Rd vs. Rd18 HR:.82, P =.48 a Rd18 vs. MPT HR: 1., P = 1. a PFS (mos)
23 Change From Baseline FIRST Trial: EORTC QLQ-MY2 Results 23 Rd resulted in a significant reduction in patient-reported Side Effects of Tx vs. MPT at most time points More side effects 2 15 Side Effects of Tx Rd MPT Fewer side effects * * * P.5 vs. baseline (1-sample t-test). P.5 Rd vs. MPT (2-sample t-test). * * * * * * * C2D1 Mo 3 Mo 6 Mo 12 Mo 18 Visit EORTC, European Organisation for Research and Treatment of Cancer; Mo, month; MPT, melphalan, prednisone, thalidomide; Rd, lenalidomide plus low-dose dexamethasone; Tx, treatment. Facon T, et al. EHA 214: Abstract S643.
24 Treatment improved HRQoL HRQoL decreased significantly in all domains upon progression Global Health Status: Higher Score = Better Global Health Status Mean value Mean value FIRST Trial: Impact of Disease Progression Mean value Mean value Fatigue: Higher Score = Worse Fatigue *** Rd *** *** MPT *** Score Baseline Best prior to PD PD *** above Best Prior to PD: P.5 vs. baseline. +++ above PD: P.5 vs. Best Score Prior to PD. Physical Functioning: Higher Score = Better Physical Functioning Pain: Higher Score = Worse Pain Rd MPT Rd MPT *** Rd *** *** MPT *** HRQoL, health-related quality of life; MPT, melphalan, prednisone, thalidomide; PD, progressive disease; Rd, lenalidomide plus low-dose dexamethasone. Delforge M, et al. Health-Related Quality of Life in Transplant-Ineligible Patients With NDMM- Results From the FIRST Trial. ASCO 214, Abstract 8516.
25 Why is IFM 27-1/MM2/FIRST an important trial? (among others) Design: Continuous (CT) vs. Fixed Duration Therapy (FDT) - the FIRST trial compared the same regimen (Rd) given either as CT or FDT Alkylator-free vs. Alkylator-containing - without being designed to assess the role of alkylating agents Result: Continuous Rd > MPT Conclusion: A dual paradigm changing study - in a disease where alkylators and FDT have been the standard of care for decades A practice changing study - establishing continuous Rd as a new standard of care
26 Maintenance treatment with bortezomib in elderly patients with MM Median follow-up (months) Median PFS (months) 5-year OS VMP- VT/VP % VMPT-VT * 61%* *significant difference versus no maintenance 1 Mateos et al. Blood 212; 12: Palumbo et al. JCO 214, Epub 21 January
27 What is the next step forward?
28 Treatment of NDMM in Elderly Patients Landscape and Perspectives < VMP # Vd? Alternating regimens 6? VMP-Daratumumab 1 MP < MPT < Rd Rd-MLN Rd-Elotuzumab 3 Rd-Daratumumab 4 < MPR-R MPT-T MP-Carfilzomib 5 1 MMY37; 2 Tourmaline 2, clinical trial.gov ref: NCT Accessed June 214; 3 Eloquent 1, clinical trial.gov ref: NCT Accessed June 214; 4 MMY38; 5 Clarion, clinical trial.gov ref: NCT Accessed June 214; 6 Mateos et al. ASH 213, abs 43.
29 The fresh wind of Alternating regimens 1. Are they truly innovative? 2. The right way to manage multiple novel agents? Or a good idea only at first sight? 3. A way to avoid the VMP vs Rd debate? 4. Will they be really transformative?
30 Bersagel et al. NEJM. 1979;31:743-49
31 Alternating regimens as a way to manage multiple novel agents From financially acceptable to financially lethal VMP Rd VMP Rd VD Rd VD Rd VD ixazomib Rd VD ixazomib Rd anti CD38 VD ixazomib Rd VD ixazomib Rd anti CD38/Elotuzumab VD ixazomib Rd VD ixazomib Rd
32 Patients (%) Challenges and perspectives with transplantineligible patients Conclusion 1 During the past 1 years significant progress has been made in the management of transplant-ineligible MM patients Median PFS has increased from 1 15 to 25 3 months Median OS has increased from 3 to approx. 6 months OS (months) Treatment O/N Survival time median ± Standard Error (month) MP 16/ ± 3.6 M + DEX 97/ ± 3.1 DEX 11/ ± 2. DEX + IFN 12/ ± 5.3 Facon T, et al. Blood. 26;17: ; Facon T et al. Blood. 213; 122:abstract 2.
33 Patients (%) Challenges and perspectives with transplantineligible patients Conclusion 1 During the past 1 years significant progress has been made in the management of transplant-ineligible MM patients Median PFS has increased from 1 15 to 25 3 months Median OS has increased from 3 to approx. 6 months 1 First Trial: year OS Rd (n= 535) 59.4% Rd18 (n= 541) 55.7% MPT (n= 547) 51.4% OS (months) Treatment O/N Survival time median ± Standard Error (month) MP 16/ ± 3.6 M + DEX 97/ ± 3.1 DEX 11/ ± 2. DEX + IFN 12/ ± 5.3 Facon T, et al. Blood. 26;17: ; Facon T et al. Blood. 213; 122:abstract 2.
34
35 72 wks Patients (%) Patients (%) PFS: FIRST and MM-15 Trials 35 FIRST Trial: PFS (Median follow-up 37 mos) MM-15: PFS (Median follow-up 3 mos) Median PFS Median PFS 1 Rd (n = 535) Rd18 (n = 541) 25.5 mos 2.7 mos 1 MPR-R (n = 152) MPR (n = 153) 31 mos 14 mos MPT (n = 547) 21.2 mos MP (n = 154) 13 mos 8 6 Hazard ratio Rd vs. MPT:.72; P =.6 Rd vs. Rd18:.7; P =.1 Rd18 vs. MPT: 1.3; P = Hazard ratio MPR-R vs. MPR:.49; P <.1 MPR-R vs. MP:.4; P < PFS (mos) PFS (mos) Facon T, et al. Blood. 213;122:abstract 2. Dimopoulos MA, et al. Blood. 213;122:abstract 45.
36 Thalidomide enters the treatment of multiple myeloma Miami, December 4 8, 1998 Full publication in: Singhal S, et al. N Engl J Med. 1999;341:
37 MPT vs MP for elderly NDMM patients: Meta-analysis of 1685 individual-patient data from 6 trials Survival proportion PFS HR=.67 in favor of MPT, p<.1 Median 14.9 mos ( ) Median 2.3 mos ( ) MPT MP months OS HR=.83 in favor of MPT, p=.5* Median 39.3 mos ( ) Median 32.7 mos ( ) MPT MP months *Cox model for treatment, with analysis stratified by study using a random effects (frailty) model Fayers et al. Blood 211;118:
38 Patients without event (%) Patients without event (%) VISTA Trial: MP + Bortezomib (VMP) vs. MP Bortezomib twice a week x 4 cycles + weekly x 5 cycles RR (CR) (%): 71(3) vs. 35(4) TTP OS VMP MP VMP: 24. months MP: 16.6 months, P < Median follow-up 6 months Median OS: VMP: 56m MP: 43m, P = Time (months) Time (months) San Miguel et al. JCO 213; 31(4):
39 Change From Baseline Change From Baseline Change From Baseline Change From Baseline FIRST Trial: EORTC QLQ-C3 Results Scores improved significantly from baseline at most time points across Tx groups 39 Improved 2 Global Health Status 2 Physical Functioning 1 * * * * * * * * 1 * * * * * * * 1 Rd MPT 1 Rd MPT Decreased 2 C2D1 Mo 3 Mo 6 Mo 12 Mo 18 Visit 2 C2D1 Mo 3 Mo 6 Mo 12 Mo 18 Visit Increased Decreased 2 1 ** * P.5 vs. baseline (1-sample t-test). 1 2 * Fatigue * Visit * C2D1 Mo 3 Mo 6 Mo 12 Mo 18 Rd MPT ** * Pain * * * ** C2D1 Mo 3 Mo 6 Mo 12 Mo 18 Visit Rd MPT EORTC, European Organisation for Research and Treatment of Cancer; MPT, melphalan, prednisone, thalidomide; Rd, lenalidomide, low-dose dexamethasone; Tx, treatment. Delforge M, et al. Health-Related Quality of Life in Transplant-Ineligible Patients With NDMM- Results From the FIRST Trial. ASCO 214, Abstract 8516.
40 FIRST Trial - Age Analysis: Adjusted Starting Doses 4 Drugs/Regimens LEN (21/28 days) Adjustment 75 yrs > 75 yrs CrCl: < 3 ml/min CrCl: 3-5 ml/min CrCl: > 5 ml/min DEX (1, 8, 15, 22/28 days) MEL (1-4/42 days) PRED (1-4/42 days) THAL (28/28 days) N/A CrCl: < 5 ml/min ANC < 1,5/µl Platelet count: < 1,/µL N/A N/A ANC, absolute neutrophil count; CrCl, creatinine clearance; DEX, dexamethasone; LEN, lenalidomide; MEL, melphalan; N/A, not applicable; PRED, prednisone; QOD, once every 2 days; THAL, thalidomide. Hulin C, et al. FIRST Trial Effect of Age in NDMM patients. ASH 214, abstract #81.
41 FIRST Trial - Age Analysis: Adjusted Starting Doses 41 Adjustment 75 yrs > 75 yrs Drugs/Regimens LEN (21/28 days) CrCl: < 3 ml/min 15 mg QOD 15 mg QOD CrCl: 3-5 ml/min 1 mg 1 mg CrCl: > 5 ml/min 25 mg 25 mg DEX (1, 8, 15, 22/28 days) MEL (1-4/42 days) PRED (1-4/42 days) THAL (28/28 days) N/A CrCl: < 5 ml/min ANC < 1,5/µl Platelet count: < 1,/µL N/A N/A ANC, absolute neutrophil count; CrCl, creatinine clearance; DEX, dexamethasone; LEN, lenalidomide; MEL, melphalan; N/A, not applicable; PRED, prednisone; QOD, once every 2 days; THAL, thalidomide. Hulin C, et al. FIRST Trial Effect of Age in NDMM patients. ASH 214, abstract #81.
42 Challenges and perspectives with transplantineligible patients Conclusion 2 High-risk patients still have a very poor outcome with first generation novel agents There is a need for adequate risk assessment and innovative therapy Frail patients remain a challenge Assessment of organ function, comorbidities, frailty, and disability should be considered Additional progress is anticipated with 2 nd /3 rd generation PIs, IMiDs, monoclonal Abs, and innovative treatment regimens
43 What are the most important challenges? Discussion on cytogenetics and frailty
44 Probability of OS Probability of OS Cytogenetic abnormalities are a major prognostic factor in elderly patients with MM the IFM experience 1,89 patients (median age 72, range 66 94), including 1,95 patients with updated data on treatment modalities and survival 1. OS according to t(4:14) 1. OS according to del(17p).75 p < 1.4 p < t(4:14) neg t(4:14) pos Time (years) Whatever the treatment, t(4;14) and del(17p) were associated with shorter PFS and OS; similar results were achieved in the subgroup of 335 patients > 75 years.25. del(17p) < 6 del(17p) Time (years) Avet-Loiseau H, et al. J Clin Oncol. 213;31:286-9
45 The challenge of high-risk CA [t(4;14), del(17p), t(14;16)] in NDMM elderly patients Study No of patients with high-risk CA Outcome of high-risk CA patients MPT/MP 1 NR NR CTDa/MP 1 (MRC Myeloma IX) NR CTDa does not overcome the effect of high-risk CA and not significantly better than MP in highrisk CA RD/Rd 2 (E4A3) 21 2y OS=76% for high-risk CA vs 91% VMP/MP 3 (VISTA) VMP/VTP VT/VP 4 (GEM-5) Absence of OS benefit, median OS 44.1mo. VMP vs 5.6 mo., MP Adverse prognosis of both t(4;14) and del (17p) regardless of induction and maintenance. Median OS t(4;14)=29 mo., del(17p) = 27mo. First generation novel agents do not overcome the negative prognosis of high-risk CA in newly diagnosed elderly patients with MM 1. Bergsagel PL, et al. Blood 213;121: Rajkumar SV, et al. Lancet Oncology 21;11: San Miguel J, et al. JCO 213;31: Mateos MV, et al. Blood 211; 118:
46 Higher risk of mortality in patients 75 years of age Retrospective meta-analysis of 4 EU phase III trials (N = 1,435) with MP, MPT, VMP, and VMPT Median follow up 33 months Median OS in total population 5 months Estimated 3-year OS 68% in patients < 75 years of age vs 57% in patients 75 years of age (HR 1.44, CI , p <.1) HR (95% CI) p value All 1.44 (1.2.72) <.1 MP 1.21 ( ).21 MPT 1.12 ( ).49 VMP 1.62 ( ).3 VTP/VMPT 3.2 ( ) <.1.1 Higher mortality in patients < 75 years of age 1 1 Higher mortality in patients 75 years of age Bringhen S, et al. Haematologica. 213; 98:98
47 Factors associated with shorter survival Advanced age, renal failure, severe cardiac/infective AEs and drug discontinuation were associated with shorter OS PN was associated with longer OS HR (95% CI) p value Male 1.13 ( ).17 Age 75 years 1.36 ( ).1 Serum creatinine 2 mg/dl 1.59 ( ).3 Grade 3/4 haem AEs 1.24 ( ).21 Grade 3/4 non-haem AEs 1.72 ( ).4 cardiac 2.61 ( ).1 infections 2.46 ( ) <.1 GI 1.89 ( ).8 VTE 1.14 ( ).79 PN.29 ( ).8 Drug discontinuation 1.61 ( ) Lower mortality 1 1 Higher mortality Bringhen S, et al. Haematologica. 213; 98:98
48 Patients (%) Frailty is Stronger Predictor of Overall Survival than ISS or FISH (GIMEMA) yr OS Fit 96% Unfit 93% Frail 78% Unfit vs Fit, HR = 1.61 P =.42 Frail vs Fit, HR = 3.57 P < Months Multivariate Analysis Unfit vs. Fit 1.24 (.74, 2.8) Frail vs. Fit 3.11 (1.97, 4.9) ISS 3 vs. ISS (1.23, 2.54) HR vs. SR FISH 1.83 (1.26, 2.63) ECOG 2-3 vs (.81, 1.76) Lower risk Death FIT ISS 1-2 FISH neg Higher risk Death FRAIL ISS 3 FISH pos Fit defined as: score = ; Unfit defined as: score = 1; Frail defined as: score > 2. Mina R, et al. EHA 19 th Congress; June 12-15, 214: abstract P354.
49 IMWG consensus statement on the treatment of Transplant-ineligible NDMM patients Newly diagnosed, symptomatic MM patients NOT eligible for high dose therapy (MEL2) and SCT Assessment of patient status: Presence of comorbidities and/or limits in mental or mobility functions Specific index and scores can be used Very fit Fit Unfit Reducedintensity ASCT (MEL 1) MPT MPV/VMPT-VT VCD/VRD MPR-R/Rd Low-dose MPT/MPV Vd/Rd MPR-R, melphalan, prednisone, lenalidomide followed by lenalidomide maintenance; MPT, melphalan, prednisone, thalidomide; MPV, bortezomib, melphalan, prednisone; Rd, lenalidomide, low-dose dexamethasone; Vd, bortezomib, low-dose dexamethasone; VMPT-VT, bortezomib, melphalan, prednisone, thalidomide followed by bortezomib plus thalidomide maintenance Palumbo A, et al. J Clin Oncol. 214;32:587-6
50
51 Patients surviving (%) Continued Improvement in Survival Since the Introduction of Novel Agents 1,56 patients grouped into and cohorts Survival improved over time, particularly in patients aged > 65 years (P =.1) 1 8 Diagnosed Survival P Median OS, years 4.6 NR year survival, % Diagnosed year estimated OS, % 2 Overall > 65 years < 65 years NS Follow-up from diagnosis (years) Kumar SK, et al. Leukemia. 214;28(5):
52 Refresher on MPT and VMP data A journey back in time... MPT: melphalan, prednisone, thalidomide VMP: bortezomib, melphalan, prednisone
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationManagement of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationDisclosures for Alessandra Larocca, MD
Disclosures for Alessandra Larocca, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria No relevant conflicts of interest to declare No relevant conflicts of interest
More informationMultiple Myeloma: Approach to the Elderly
Multiple Myeloma: Approach to the Elderly Peter Anglin MD, FRCPC, MBA Stronach Regional Cancer Centre Newmarket, ON PMH Myeloma Day May 12, 2017 Peter Anglin MD Disclosures Speakers Bureau Advisory Boards
More informationChristine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationTreatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationUpdates in Multiple Myeloma: 12 months in 10 minutes
Updates in Multiple Myeloma: 12 months in 10 minutes Aaron Rosenberg MD, MS Assistant Prof. Medicine UC Davis Comprehensive Cancer Center Division of Hematology and Oncology Outline Standard of care for
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationMaintenance therapy after autologous transplantation
Maintenance therapy after autologous transplantation Sonja Zweegman MD PhD Department of Hematology Amsterdam The Netherlands Disclosures Research funding from Celgene, Takeda and Janssen Participation
More informationIs Myeloma Curable in 2012?
Is Myeloma Curable in 2012? YES Cure is living long enough to die of another cause April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist,
More informationMULTIPLE MYELOMA AFTER AGE OF 80 YEARS
MULTIPLE MYELOMA AFTER AGE OF 80 YEARS C. Hulin CHU Nancy, France Intergroupe Francophone du Myelome (IFM) Epidemiology SEER Program between 1990-2004: 17 330 MM cases, 51% 70 y and 20% 80 y. Brenner et
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More informationMethods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationMULTIPLE MYELOMA. The clonoseq Assay can predict progressionfree survival in myeloma patients
MULTIPLE MYELOMA With current therapies, complete response (CR) is reached in 3-5% of multiple myeloma () patients. 1 However, most of these patients will experience relapse due to the persistence of residual
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationModule 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning
Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Challenge Question: Role of Autologous Stem Cell Transplant Which of the following is true about eligibility for high-dose
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationOncology Highlights ASCO 2011 MULTIPLE MYELOMA
Oncology Highlights ASCO 211 MULTIPLE MYELOMA July 211 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist, Mayo Clinic Arizona Disclosures
More informationMultiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationThe TOURMALINE-MM1 study: results and expert insights
The TOURMALINE-MM1 study: results and expert insights Professor Faith Davies UAMS Myeloma Institute, Arkansas, USA This educational meeting was organised and fully funded by Takeda UK Ltd. Takeda medicines
More informationMULTIPLE MYELOMA. The clonoseq Assay can predict progressionfree survival in myeloma patients
MULTIPLE MYELOMA With current therapies, complete response (CR) is reached in 3-5% of multiple myeloma () patients. 1 However, most of these patients will experience relapse due to the persistence of residual
More informationShould we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain
Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option
More informationMYELOMA MAINTENANCE BEST PRACTICES:
MYELOMA MAINTENANCE BEST PRACTICES: POST THERAPY & POST TRANSPLANT Aric Hall, MD Assistant Professor University of Wisconsin Hospital and Clinics INTRODUCTION MYELOMA Clonal plasma cell malignancy leading
More informationMAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
More informationMultiple Myeloma in the Elderly: When to Treat, When to Go to Transplant
Multiple Myeloma in the Elderly: When to Treat, When to Go to Transplant Review Article [1] October 15, 2010 By Jean-luc Harousseau, MD [2] Until recently, standard treatment of multiple myeloma (MM) in
More informationBest of ASH 2017 DR. BRIAN DURIE. Brian GM Durie, MD Thursday, January 11, 2018
Best of ASH 2017 DR. BRIAN DURIE Brian GM Durie, MD Thursday, January 11, 2018 1 ASH Overview 2017 Total myeloma abstracts: 981 Important/Interesting: oral ~40 posters ~60 100 2 Which abstracts impact
More informationwhich to base economic assessment of the products available to treat this hematologic
special feature Measuring Value of Multiple Myeloma Therapies by Gary M. Owens, MD, Gary Owens Associates As recent therapies for multiple myeloma (MM) have provided significant improvements in the prognosis
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationComorbidities in Multiple Myeloma
Comorbidities in Multiple Myeloma Michel Delforge, MD, PhD University Hospital Leuven Leuven, Belgium COMy, Bangkok 12 may 2014 Comy Meeting, Bangkok, 12 may 2014 Disclosures Advisory board: Janssen,
More informationModified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
ORIGINAL ARTICLE 218 Oct 26. [Epub ahead of print] https://doi.org/1.394/kjim.218.144 Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
More informationAutologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy
Autologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy Donna E. Reece, M.D. Princess Margaret Hospital Toronto, ON CANADA 10 December 2011 ASCT in Myeloma..
More informationTREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE
TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE PRESENTED BY: Pooja Chaukiyal MD Hematologist/Oncologist New York Oncology Hematology Albany, NY April 16, 2016 Background The prognosis for patients
More informationKalyan Nadiminti, MBBS 4/13/18
A Single Autologous Stem Cell Transplant (ASCT) followed by two years of post-transplant therapy is safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective
More informationAperTO - Archivio Istituzionale Open Access dell'università di Torino
AperTO - Archivio Istituzionale Open Access dell'università di Torino Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis
More informationMyeloma and renal failure Future directions. Karthik Ramasamy
Myeloma and renal failure Future directions Karthik Ramasamy Overview Historical perspective & Background Drug interventions & trials OPTIMAL Trial Future directions Burden of disease Upto 40% of newly
More informationMeu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin
Meu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin Post Auto HCT Options for MM Maintenance Lenalidomide vs.
More informationTreatment strategies for non-transplant-eligible patients
Treatment strategies for non-transplant-eligible patients Thierry FACON, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France An average elderly MM patient.. 74 year
More informationAcademia Pharma Intersect: Myelomas
The Oncologist Academia Pharma Intersect: Myelomas European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses HEINZ LUDWIG, a HERVÉ AVET-LOISEAU, b JOAN BLADÉ, c
More informationDevelopments in the Treatment of Multiple Myeloma Kenneth C. Anderson, M.D.
Developments in the Treatment of Multiple Myeloma Kenneth C. Anderson, M.D. Kraft Family Professor of Medicine Harvard Medical School Director, Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer
More informationExperience with bortezomib (Velcade) in multiple myeloma. Peter Černelč Clinical center Ljubljana Department of Haematology
Experience with bortezomib (Velcade) in multiple myeloma Peter Černelč Clinical center Ljubljana Department of Haematology Our experience with bortezomib (Velcade) in multiple myeloma 1. Our first experience
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationNew standards of care for NDMM patients not eligible for transplant
New standards of care for NDMM patients not eligible for transplant Thierry FACON, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Epidemiology of Elderly Changing
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationStudy Objectives: GMMG MM5
Study Objectives: GMMG MM5 1.) Demonstration of non-inferiority of VCD induction therapy compared to PAd induction therapy with respect to response rate (very good partial remission or better; response
More informationCurrent management of multiple myeloma. Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School
Current management of multiple myeloma Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School JorgeJ_Castillo@dfci.harvard.edu Multiple myeloma MM is a plasma cell neoplasm characterized
More informationWhere to go from Here and Future Trials?
Where to go from Here and Future Trials? Does our understanding of Pathogenesis, Disease management and Novel drugs get us closer to a cure of MM? Thierry FACON, MD Professor of Hematology Service des
More informationMyeloma care and proteasome inhibitors. Brendan M. Weiss, MD Abramson Cancer Center University of Pennsylvania
Myeloma care and proteasome inhibitors Brendan M. Weiss, MD Abramson Cancer Center University of Pennsylvania Why care about CV toxicities in MM? Median age 72 years About 2/3 have CV disease at baseline
More informationMultiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D.
Multiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D. Multiple Myeloma Facts Second most prevalent hematologic neoplasm Nearly 24, new cases diagnosed in the US per year and 11, worldwide
More informationMultiple Myeloma: Miami, FL Current Treatment Paradigms and Future Directions December 18, 2009
Welcome to Master Class for Oncologists Miami, FL December 18, 29 Session 5: 11: AM - 11:45 AM Multiple Myeloma: Current Treatment Paradigms and Future Directions Speaker: Kenneth C. Anderson, MD Chief,
More information